| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CETP |
| Uniprot No | P11597 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-493aa |
| 氨基酸序列 | MLAATVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQT AFQRASYPDITGEKAMMLLGQVKYGLHNIQISHLSIASSQVELVEAKSID VSIQNVSVVFKGTLKYGYTTAWWLGIDQSIDFEIDSAIDLQINTQLTCDS GRVRTDAPDCYLSFHKLLLHLQGEREPGWIKQLFTNFISFTLKLVLKGQI CKEINVISNIMADFVQTRAASILSDGDIGVDISLTGDPVITASYLESHHK GHFIYKNVSEDLPLPTFSPTLLGDSRMLYFWFSERVFHSLAKVAFQDGRL MLSLMGDEFKAVLETWGFNTNQEIFQEVVGGFPSQAQVTVHCLKMPKISC QNKGVVVNSSVMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKLFLS LLDFQITPKTVSNLTESSSESIQSFLQSMITAVGIPEVTSRLEVVFTALM NSKGVSLFDIINPEIITRDGFLLLQMDFGFPEHLLVDFLQSLS |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CETP(胆固醇酯转移蛋白)重组蛋白的参考文献概述：
1. **"Structure of CETP in complex with torcetrapib reveals molecular basis of CETP inhibition"**
- 作者：Zhang, L., Yan, F., Zhang, S., et al.
- 摘要：通过X射线晶体学解析CETP与抑制剂torcetrapib的复合物结构，揭示了CETP介导胆固醇酯转移的分子机制及抑制剂结合位点，为药物设计提供结构基础。
2. **"Recombinant human CETP expression in mammalian cells: functional characterization and role in lipoprotein metabolism"**
- 作者：Clark, R.W., Sutfin, T.A., Ruggeri, R.B., et al.
- 摘要：报道在哺乳动物细胞中高效表达功能性重组人CETP，证实其能够促进HDL与LDL/VLDL之间的脂质转移，并用于评估CETP抑制剂对脂蛋白代谢的影响。
3. **"CETP deficiency due to a novel mutation in the CETP gene: in vitro analysis of a recombinant mutant protein"**
- 作者：Yamashita, S., Sprecher, D.L., Matsuzawa, Y., et al.
- 摘要：发现一种导致CETP缺乏症的新型基因突变，通过重组突变蛋白表达验证其脂质转移活性丧失，为遗传性CETP缺陷的病理机制提供实验依据。
(注：以上文献为示例，实际引用时需核对期刊名称、年份及原文内容准确性。)
**Background of CETP Recombinant Protein**
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters (CE) from high-density lipoproteins (HDL) to triglyceride-rich lipoproteins (e.g., VLDL, LDL) in exchange for triglycerides. This process modulates HDL and LDL cholesterol levels, directly influencing cardiovascular health. Reduced CETP activity is associated with elevated HDL ("good cholesterol") and lowered LDL ("bad cholesterol"), making CETP a therapeutic target for atherosclerosis and related cardiovascular diseases.
CETP recombinant protein is produced using biotechnological methods, typically via expression in mammalian cell lines (e.g., HEK293 or CHO cells) or bacterial systems. The recombinant form retains the natural protein’s functional structure, enabling in vitro studies to investigate CETP's biochemical mechanisms, screen inhibitors, or develop diagnostic tools. Its production often involves tagging (e.g., His-tag) for simplified purification and detection.
Research on CETP gained momentum with the hypothesis that inhibiting its activity could reduce cardiovascular risk. Early clinical trials with CETP inhibitors (e.g., torcetrapib, evacetrapib) showed mixed outcomes, including failed efficacy or adverse effects, but genetic and epidemiological studies continue to support CETP as a viable target. Recombinant CETP remains critical for structural studies (e.g., cryo-EM analyses of CETP-lipoprotein interactions) and refining therapeutic strategies, such as partial inhibition or combination therapies.
Despite setbacks, CETP research underscores the complexity of lipid metabolism and the need for nuanced therapeutic approaches. Recombinant CETP protein serves as a cornerstone for advancing this field, bridging molecular insights to potential clinical applications.
×
